Shiyao Group (01093.HK): JMT106 (bispecific fusion protein drug) receives approval for clinical trials in China.

Zhitan Finance APP News, Shiyao Group (01093.HK) announced that the group's developed bispecific fusion protein drug JMT106 (the product) has been approved by the National Medical Products Administration of the People's Republic of China for clinical trials in China. The product has also received approval from the US Food and Drug Administration (FDA) to conduct clinical trials in the United States in January 2024.